Novel nonantibiotic therapies for pneumonia: Cytokines and host defense

Chest

Volumn 119, Issue 2 SUPPL., 2001, Pages 419S-425S

  Nelson, S ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cytokines; Granulocyte colony stimulating factor; Inflammatory response; Interleukins; Pneumonia; Tumor necrosis factor

Indexed keywords

CYTOKINE; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 8; TUMOR NECROSIS FACTOR;

ADJUVANT THERAPY; BACTERIAL INFECTION; CELL KILLING; DRUG EFFECT; HOST RESISTANCE; HUMAN; LUNG ALVEOLUS MACROPHAGE; MACROPHAGE ACTIVATION; PHAGOCYTOSIS; PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

EID: 0035110325     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Normal and defective respiratory host defenses
2. The alveolar macrophage
3. Macrophages and polymorphonuclear neutrophils in lung defense and injury
4. Pathophysiology of pneumonia
5. Expression and regulation of chemokines in bacterial pneumonia
6. Cytokines in context
7. Shock and tissue injury induced by recombinant human cachectin
8. An endotoxin-induced serum factor that causes necrosis of tumors
9. Tumor necrosis factor (TNF)
10. Compartmentalization of intraalveolar and systemic lipopolysaccharide-induced tumor necrosis factor and the pulmonary inflammatory response
11. Adenovirus-mediated blockade of tumor necrosis factor in mice protects against endotoxic shock yet impairs pulmonary host defense
12. Anti-tumor necrosis factor-α antibody suppresses pulmonary antibacterial defenses
13. Compartmentalization of the acute cytokine response in humans after intravenous endotoxin administration
14. Compartmentalized cytokine production within the human lung in unilateral pneumonia
15. Interleukin-8 (IL-8): The major neutrophil chemotactic factor in the lung
16. Compartmentalized IL-8 and elastase release within the human lung in unilateral pneumonia
17. Neutralization of macrophage inflammatory protein-2 attenuates neutrophil recruitment and bacterial clearance in murine Klebsiella pneumonia
18. Protective effects of tumor necrosis factor in experimental Legionella pneumophila infections of mice via activation of PMN function
19. Tumor necrosis factor mediates lung antibacterial host defense in murine Klebsiella pneumonia
20. Antibody-mediated depletion of tumor necrosis factor-α impairs pulmonary host defenses to Legionella pneumophila
21. Passive immunization against tumor necrosis factor-α impairs host defense during pneumococcal pneumonia in mice
22. Tumor necrosis factor-α is required in the protective immune response against Mycobacterium tuberculosis in mice
23. In vitro activation of the antibacterial activity of human pulmonary macrophages by recombinant γ interferon
24. Local activation of mononuclear phagocytes by delivery of an aerosol of recombinant interferon-γ to the human lung
25. Expression of pro-inflammatory cytokines by flow-sorted alveolar macrophages in severe pneumonia
26. Monocyte deactivation in septic patients: Restoration by IFN-γ treatment
27. Interleukin-10 impairs host defense in murine pneumococcal pneumonia
28. Neutralization of IL-10 increases survival in a murine model of Klebsiella pneumonia
29. Interleukin-12
30. IL-2 gene therapy protects mice in lethal Klebsiella pneumonia
31. Granulocye colony-stimulating factor: Role and relationships in infectious diseases
32. Spontaneous release of granulocyte colony-stimulating factor (G-CSF) by alveolar macrophages in the course of bacterial pneumonia and sarcoidosis: Endotoxin-dependent and endotoxin-independent G-CSF release by cells recovered by bronchoalveolar lavage
33. Granulocyte colony-stimulating factor and modulation of inflammatory cells in sepsis
34. Protective effect of recombinant human granulocyte colony-stimulating factor against pneumococcal infections in splenectomized mice
35. Granulocyte colony-stimulating factor versus placebo in addition to penicillin G in a randomized blinded study of Gram-negative pneumonia sepsis: Analysis of survival and multisystem organ failure
36. Filgrastim in the treatment of hospitalized patients with community acquired pneumonia (CAP)
37. Time to resolution of morbidity: An endpoint for assessing the clinical cure of community-acquired pneumonia
38. Filgrastim (rhuG-CSF) enhances ciprofloxacin uptake and bactericidal activity of human neutrophils in vitro
39. Therapeutic efficacy of granulocyte colony-stimulating factor alone and in combination with antibiotics against Pseudomonas aeruginosa infection in mice